Stay updated with breaking news from Ryan Saadi. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
WARREN, N.J.--(BUSINESS WIRE)--#BSA--Tevogen Bio is pleased to announce that its founder and CEO, Dr. Ryan Saadi, has been named the recipient of the prestigious Boy Scouts of America Distinguished Citizen Award. Dr. Saadi will accept the award at the Boy Scouts of America Patriots' Path Council's 5th Project STEM A...
Tevogen’s investigational precision T cell product, TVGN-489, is a genetically unmodified, off-the-shelf, allogeneic cytotoxic CD8+ T lymphocyte (CTL) product with activity against multiple precise targets across the entire SARS-CoV-2 genome.The immunocompromised COVID-19 patients who are unable to take or unlikely...
Given that no dose limiting toxicities or treatment-related adverse events were observed during Tevogen’s proof-of-concept trial, in patients with SARS-CoV-2 infection, the company plans to develop target specific genetically unmodified T cell therapies for the treatment of Epstein-Barr Virus (EBV)-related cancers a...
Tevogen Bio® and Founding CEO are nominated for the 2023 Nobel Peace Prize by Curtis Patton, PhD, Professor Emeritus, Yale School of Public Health, Yale UniversityWARREN, N.J.--(BUSINESS WIRE)--#celltherapies--Tevogen Bio®, is a late-stage clinical biotechnology company specializing in the development of cellular im...
No dose-limiting toxicities or significant treatment-related adverse events were observed for any patient at any dose levelWARREN, N.J.--(BUSINESS WIRE)--#COVID19--Tevogen Bio, a late stage clinical biotechnology company specializing in the development of cell and gene therapies in oncology, neurology, and virology,...